We are SphereBio. We deliver the complete tumor fingerprint to the immune system, creating cancer vaccines that finally work.

1 in 6 people worldwide are killed by cancer.
$80B+ is spent every year on oncology clinical trials.
97% of these trials fail.
Billions are spent. Millions of lives are lost.
The world is waiting for a breakthrough.

The Evolution of the Fight

First came brute force:

Radiotherapy & Chemotherapy

Then came precision:

Targeted Therapies

The breakthrough was unlocking:

Immunotherapies that unleashed the immune system.

But the next frontier is not just unlocking. It's training.

Why is there still no effective cancer vaccine?

Think of it like a FedEx delivery. For it to work, two things must be perfect: the content of the package and the delivery address.

The Content Problem

Current approaches (mRNA, peptides) only show the immune system the tip of the iceberg. They miss the vast majority of tumor signals.

The Delivery Problem

Even if the content is right, the delivery fails. ~99% of molecules get trapped and destroyed, a massive bottleneck for the entire industry.

The SphereBio Solution: The Whole Iceberg, Delivered.

1. The Content: The Entire Iceberg

Our OncoSpheres™ use nanoparticles from the patient’s own tumor, carrying the full antigenic fingerprint—including signals invisible to other tech.

2. The Delivery: A Molecular Key

Our proprietary XSpheres™ platform uses fusogenic proteins that bypass the delivery barrier, ensuring over 99% of the cargo arrives intact.

SphereBio = The FedEx of Cancer Vaccines.
The right package, delivered to the right address. Every time.

Our Unfair Advantage: Built on Solid Ground

1. Proprietary & Patented Technology

  • SphereEngine™: AI-driven protein design.
  • XSpheres™: Next-gen delivery platform.
  • Rock-solid IP: Granted patents, managed by Wilson Sonsini.

2. World-Class Validation

  • Tech co-funded by Amazon (AWS).
  • AI platform presented at ASCO.
  • Recognized by MIT's accelerator & Pharma executives.
  • Prestigious collaborations with Dana Farber & Brigham and Women's.

3. A Capital-Efficient Business Model

  • Focus on early licensing deals with pharma.
  • De-risks development & accelerates revenue.
  • Upfront payments, milestones, and royalties.

A Multi-Billion Dollar Frontier

Total Addressable Market $500B+ Personalized Therapeutics Market
Serviceable Addressable Market $200B+ All Solid Tumor Vaccines Market
Serviceable Obtainable Market $3B Our Initial Target: Glioblastoma

Built for This Mission

The right blend of world-class science and proven business execution.

Julieta Porta

CEO

Vision, strategy, and a global network across pharma and biotech. Expert in translating deep science into capital-efficient business models.

Martín Guerrero

CMO

Clinical development and medical strategy expert. Deep understanding of the immuno-oncology landscape and regulatory pathways.

Guido Molina

CSO

The scientific mind behind the platform. Pioneer in nanotechnology and protein engineering, driving our R&D and IP portfolio.

The Ask

$1M
Pre-Seed Round

Use of Funds:

  • Complete preclinical validation for OncoSpheres™ in GBM.
  • Expand the scientific & technical team.
  • Strengthen our IP portfolio.

Roadmap to Value Creation

Current Position

$532K raised, tech validated, strong IP.

Next 18-24 Months

Complete preclinical validation & secure first partnership discussions.

Key Inflection Point

Secure First Early Licensing Deal. (Upfront Payments + Milestones)

Future Growth

Expand platform to new solid tumors and indications.

The era of 97% failure is over.

SphereBio is not just another therapy; it's a scalable platform to create a new generation of smart, effective, and personalized medicines.

Join Us
```